Stocktoria
Skye Bioscience, Inc. SKYE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-02-24
Skye Bioscience, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | — | — | — | $6.0M | $2.9M | $1.9M | $2.2M | $329,966 | $311,302 | $939,040 |
| Operating income | -$58.2M | -$30.2M | -$34.7M | -$18.3M | -$7.8M | -$6.3M | -$6.6M | -$4.7M | -$3.9M | -$4.5M |
| Interest expense | $0 | $749,308 | $906,270 | $665,133 | $769,159 | $706,385 | $1.0M | $94,763 | $667 | — |
| Income tax | $5,400 | $10,071 | $3,600 | $6,741 | $2,100 | $1,600 | $1,600 | $1,642 | $1,600 | $1,600 |
| Net income | -$55.9M | -$26.6M | -$37.6M | -$19.5M | -$8.5M | -$6.6M | $1.1M | -$19.2M | -$3.1M | -$3.2M |
| EPS (diluted) | $-1.41 | $-0.73 | $-5.37 | $-8.77 | $-0.02 | $-0.03 | $-0.05 | $-0.16 | $-0.11 | $-0.17 |
| Operating cash flow | -$43.1M | -$25.2M | -$14.0M | -$12.7M | -$6.5M | -$6.1M | -$6.0M | -$3.9M | -$3.3M | -$3.6M |
| Free cash flow | -$43.1M | -$26.8M | -$14.0M | -$12.8M | -$6.6M | -$6.1M | — | -$3.9M | -$3.4M | -$3.6M |
| Cash & equivalents | $5.9M | $68.4M | $1.3M | $1.2M | $9.0M | $2.5M | $1.8M | $1.9M | $259,955 | $64,820 |
| Total assets | $28.3M | $72.8M | $11.9M | $9.1M | $9.9M | $2.7M | $2.0M | $2.0M | $557,218 | $323,363 |
| Total liabilities | $8.3M | $4.6M | $14.1M | $12.1M | $4.0M | $2.2M | $1.4M | $17.5M | $1.4M | $1.8M |
| Shareholders' equity | $20.0M | $68.2M | -$2.1M | -$3.0M | $5.9M | $450,786 | $548,058 | -$15.6M | -$3.6M | -$2.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth | — | — | — | — | — | -723.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.